Cargando…
Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations
BACKGROUND: Different approaches have been proved effective for combating the COVID-19 pandemic. Accordingly, in silico drug repurposing strategy, has been highly regarded as an accurate computational tool to achieve fast and reliable results. Considering SARS-CoV-2's structural proteins and th...
Autores principales: | Mahdian, Soodeh, Zarrabi, Mahboobeh, Panahi, Yunes, Dabbagh, Somayyeh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904474/ https://www.ncbi.nlm.nih.gov/pubmed/33649734 http://dx.doi.org/10.1016/j.imu.2021.100541 |
Ejemplares similares
-
Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]
por: Mahdian, Soodeh, et al.
Publicado: (2023) -
Inhibition of HEV Replication by FDA-Approved RdRp
Inhibitors
por: Hooda, Preeti, et al.
Publicado: (2023) -
Effectiveness of Remdesivir in Comparison with Five Approved Antiviral Drugs for Inhibition of RdRp in Combat with SARS-CoV-2
por: Mahdian, Soodeh, et al.
Publicado: (2022) -
Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach
por: Molavi, Zahra, et al.
Publicado: (2021) -
Drug repurposing using computational methods to identify therapeutic options for COVID-19
por: Mahdian, Soodeh, et al.
Publicado: (2020)